- ICH GCP
- Registro de ensaios clínicos dos EUA
- Ensaio Clínico NCT06188689
Avaliação de um teste de diagnóstico clínico para CRDS (DIAGNOSE CRDS)
Avaliação de um teste de diagnóstico clínico para síndrome de deficiência de liberação de cálcio: o estudo DIAGNOSE CRDS
Calcium Release Deficiency Syndrome (CRDS) is a novel inherited arrhythmia syndrome secondary to RyR2 loss-of-function that confers a risk of sudden cardiac death. Diagnosis of CRDS presently requires cellular-based in vitro confirmation that an RyR2 variant causes loss-of-function. We hypothesize that CRDS can be diagnosed clinically through evaluation of the repolarization response to brief tachycardia, mediated by cardiac pacing, and a subsequent pause.
Visão geral do estudo
Status
Intervenção / Tratamento
Descrição detalhada
RyR2 loss-of-function variants have recently been established as causative for a new disease termed calcium release deficiency syndrome (CRDS) that confers a risk of malignant ventricular arrhythmias and sudden cardiac death. RyR2 encodes the cardiac ryanodine receptor, the calcium release channel on the sarcoplasmic reticulum that mediates excitation-contraction coupling through calcium-induced calcium-release. In contrast to CRDS, pathogenic RyR2 gain-of-function variants result in an autosomal dominant form of catecholaminergic polymorphic ventricular tachycardia (CPVT). The adrenergic-mediated ventricular arrhythmias characteristic of CPVT can be readily reproduced on exercise stress testing (EST), making EST the standard clinical diagnostic tool for CPVT.
In contrast to CPVT, the CRDS clinical phenotype is concealed with standard cardiac testing tools and its diagnosis presently requires cellular-based in vitro confirmation that an RyR2 variant causes loss-of-function. Beyond the significant time delay associated with in vitro functional analysis, this testing requires specialized expertise that is not widely available and remains research-based, making it impractical for routine use in clinical care. In this overall context, it is likely that the vast majority of global CRDS cases have yet to be diagnosed.
A prior report of an "atypical CPVT" family carrying an RyR2-p.M4109R variant observed marked and transient repolarization changes following pacing mediated tachycardia and a subsequent pause. Since publication of this report, in vitro characterization of the RyR2-p.M4109R variant has confirmed its being loss-of-function and the familial diagnosis has been revised to CRDS. Driven by these observations and promising preliminary findings, the DIAGNOSE CRDS study seeks to further investigate this apparent electrocardiographic signature of CRDS following brief tachycardia and subsequent pause as a potential method to clinically diagnose the condition.
Tipo de estudo
Inscrição (Estimado)
Estágio
- Não aplicável
Contactos e Locais
Contato de estudo
- Nome: Jason Roberts, MD MAS
- Número de telefone: 40632 905-297-3479
- E-mail: jason.roberts@phri.ca
Locais de estudo
-
-
-
Brussels, Bélgica, 1090
- Recrutamento
- Universitair Ziekenhuis Brussel
-
Contato:
- Project Manager
- Número de telefone: 905-521-2100
- E-mail: crds@phri.ca
-
Investigador principal:
- Luigi Pannone, MD
-
-
Antwerp
-
Edegem, Antwerp, Bélgica, 2650
- Recrutamento
- Antwerp University Hospital
-
Investigador principal:
- Johan Saenen, MD, PhD
-
Contato:
- Project Manager
- Número de telefone: 905-521-2100
- E-mail: crds@phri.ca
-
-
-
-
Alberta
-
Calgary, Alberta, Canadá, T2N 1N4
- Recrutamento
- University of Calgary
-
Investigador principal:
- Erkan Ilhan, MD
-
Contato:
- Project Manager
- Número de telefone: 905-521-2100
- E-mail: crds@phri.ca
-
Edmonton, Alberta, Canadá, T6G 2C8
- Recrutamento
- Alberta Health Services
-
Contato:
- Project Manager
- Número de telefone: 905-521-2100
- E-mail: crds@phri.ca
-
Investigador principal:
- Joseph Atallah, MD CM, MSc
-
-
British Columbia
-
Vancouver, British Columbia, Canadá, V6T 1Z3
- Recrutamento
- The University of British Columbia
-
Contato:
- Project Manager
- Número de telefone: 905-521-2100
- E-mail: crds@phri.ca
-
Investigador principal:
- Thomas M Roston, MD
-
Vancouver, British Columbia, Canadá, V6H 3N1
- Recrutamento
- Children's & Women's Health Centre of British Columbia
-
Contato:
- Project Manager
- Número de telefone: 905-521-2100
- E-mail: crds@phri.ca
-
Investigador principal:
- Shubhayan Sanatani, MD
-
-
Ontario
-
Hamilton, Ontario, Canadá, L8L 2X2
- Recrutamento
- Hamilton General Hospital
-
Investigador principal:
- Jason D Roberts, MD MAS
-
Contato:
- Project Manager
- Número de telefone: 905-521-2100
- E-mail: crds@phri.ca
-
London, Ontario, Canadá, N6A 5A5
- Recrutamento
- London Health Sciences Centre - University Hospital
-
Investigador principal:
- Habib R Khan, MD
-
Contato:
- Project Manager
- Número de telefone: 905-521-2100
- E-mail: crds@phri.ca
-
Ottawa, Ontario, Canadá, K1Y 4W7
- Recrutamento
- Ottawa Heart Institute
-
Investigador principal:
- Simon Hansom, MD
-
Contato:
- Project Manager
- Número de telefone: 905-521-2100
- E-mail: crds@phri.ca
-
Toronto, Ontario, Canadá, M5G 2C4
- Recrutamento
- Toronto General Hospital
-
Contato:
- Project Manager
- Número de telefone: 905-521-2100
- E-mail: crds@phri.ca
-
Investigador principal:
- Michael H. Gollob, MD, FRCP(C)
-
-
Quebec
-
Montreal, Quebec, Canadá, H1T 1C8
- Recrutamento
- Montréal Heart Institute
-
Investigador principal:
- Rafik Tadros, MD PhD
-
Contato:
- Project Manager
- Número de telefone: 905-521-2100
- E-mail: crds@phri.ca
-
Québec, Quebec, Canadá, G1V 4G5
- Recrutamento
- Institut Universitaire de Cardiologie et de Pneumologie de Québec-Université Laval
-
Investigador principal:
- Christian Steinberg, MD
-
Contato:
- Project Manager
- Número de telefone: 905-521-2100
- E-mail: crds@phri.ca
-
-
-
-
-
Aarhus, Dinamarca, DK-8200 N
- Recrutamento
- Aarhus University Hospital
-
Contato:
- Project Manager
- Número de telefone: 905-521-2100
- E-mail: crds@phri.ca
-
Investigador principal:
- Henrik Jensen, MD
-
-
-
-
California
-
San Francisco, California, Estados Unidos, 94143
- Recrutamento
- University of California
-
Contato:
- Project Manager
- Número de telefone: 905-521-2100
- E-mail: crds@phri.ca
-
Investigador principal:
- Vasanth Vedantham, MD, PhD
-
-
Massachusetts
-
Boston, Massachusetts, Estados Unidos, 02115
- Recrutamento
- Boston Children's Hospital
-
Contato:
- Project Manager
- Número de telefone: 905-521-2100
- E-mail: crds@phri.ca
-
Investigador principal:
- Dominic Abrams, MBBS, MD, MBA
-
-
Minnesota
-
Rochester, Minnesota, Estados Unidos, 55905
- Recrutamento
- Mayo Clinic
-
Contato:
- Project Manager
- Número de telefone: 905-521-2100
- E-mail: crds@phri.ca
-
Investigador principal:
- John Giudicessi, MD, PhD
-
-
Washington
-
Seattle, Washington, Estados Unidos, 98195
- Recrutamento
- University of Washington
-
Contato:
- Project Manager
- Número de telefone: 905-521-2100
- E-mail: crds@phri.ca
-
Investigador principal:
- Uyanga Batnyam, MD
-
-
-
-
New Aquitaine
-
Bordeaux, New Aquitaine, França, 33404
- Recrutamento
- CHU de Bordeaux
-
Contato:
- Project Manager
- Número de telefone: 905-521-2100
- E-mail: crds@phri.ca
-
Investigador principal:
- Frédéric Sacher, MD
-
-
-
-
-
Jerusalem, Israel, 9103102
- Recrutamento
- Shaare Zedek Medical Center
-
Contato:
- Project Manager
- Número de telefone: 905-521-2100
- E-mail: crds@phri.ca
-
Investigador principal:
- Ziv Dadon, MD
-
-
-
-
London
-
London, London, Reino Unido, WC1N 3JH
- Recrutamento
- Great Ormond Street Hospital
-
Contato:
- Project Manager
- Número de telefone: 905-521-2100
- E-mail: crds@phri.ca
-
Investigador principal:
- Luke Starling, BSc (Hons), MB BS, FRCPCH
-
-
Oxfordshire
-
Oxford, Oxfordshire, Reino Unido, OX3 9DU
- Recrutamento
- Oxford University Hospitals
-
Contato:
- Project Manager
- Número de telefone: 905-521-2100
- E-mail: crds@phri.ca
-
Investigador principal:
- Julian Ormerod, BM, Bch, FRCP
-
-
Critérios de participação
Critérios de elegibilidade
Idades elegíveis para estudo
- Filho
- Adulto
- Adulto mais velho
Aceita Voluntários Saudáveis
Gêneros Elegíveis para o Estudo
Descrição
Cohort 1: Calcium Release Deficiency Syndrome (CRDS) Cases
Inclusion criteria:
• Presence of an RyR2 variant confirmed to be loss-of-function on in vitro testing
Exclusion criteria:
• Unable to provide informed consent
Cohort 2: Catecholaminergic Polymorphic Ventricular Tachycardia (CPVT) Cases
Inclusion criteria:
- Satisfy a clinical phenotype consistent with the Expert Consensus Statement
- Presence of a confirmed or presumed pathogenic gain-of-function RyR2 variant OR homozygous or compound heterozygous for likely pathogenic/pathogenic CASQ2 variants
Exclusion criteria:
- Unable to provide informed consent
- Use of a QT prolonging medication, aside from flecainide, at the time of the burst pacing maneuvers
Cohort 3: Survivors of Unexplained Cardiac Arrest (UCA)
Inclusion criteria:
- Cardiac arrest requiring cardioversion or defibrillation that remains unexplained following an ECG, echocardiogram, coronary assessment, cardiac MRI, and exercise treadmill test
- Undergone genetic testing that includes screening of RyR2*
Exclusion criteria:
-
Unable to provide informed consent
-
Use of a QT prolonging medication at the time of the burst pacing maneuvers
- Among survivors of UCA that possess a rare RyR2 variant in the absence of a CPVT phenotype, in vitro functional testing will be performed in order to confirm it is not loss- or gain-of-function (and will be arranged through the laboratory of Dr. Wayne Chen at the University of Calgary).
Cohort 4: SVT controls
Inclusion criteria:
• Undergoing an invasive electrophysiology study
Exclusion criteria:
- Ventricular cardiomyopathy
- Ventricular pre-excitation
- Long QT syndrome
- Use of a QT prolonging medication at the time of the EP study
- Use of a Class I or Class III anti-arrhythmic drug at the time of the EP study
- Known obstructive coronary artery disease (existing coronary stenosis >50%)
- Unable to provide informed consent
Plano de estudo
Como o estudo é projetado?
Detalhes do projeto
- Finalidade Principal: Diagnóstico
- Alocação: N / D
- Modelo Intervencional: Atribuição de grupo único
- Mascaramento: Nenhum (rótulo aberto)
Armas e Intervenções
Grupo de Participantes / Braço |
Intervenção / Tratamento |
|---|---|
|
Experimental: Pacing
Separate ventricular and atrial pacing trains will be administered at different cycle lengths and the ventricular repolarization response on the first sinus beat following the subsequent pause will be evaluated. |
|
O que o estudo está medindo?
Medidas de resultados primários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
ΔT-wave amplitude value
Prazo: At time of pacing maneuver
|
T-wave amplitude on first post-pause sinus beat subtracted by the T-wave amplitude on the last sinus beat prior to pacing |
At time of pacing maneuver
|
|
ΔQT value
Prazo: At time of pacing maneuver
|
Absolute QT value on first post-pause sinus beat subtracted by the absolute QT value on the last sinus beat prior to pacing |
At time of pacing maneuver
|
Medidas de resultados secundários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Absolute QT value
Prazo: At time of pacing maneuver
|
Absolute QT value on first post-pause sinus beat |
At time of pacing maneuver
|
|
Absolute T-wave amplitude
Prazo: At time of pacing maneuver
|
Absolute T-wave amplitude on first post-pause sinus beat |
At time of pacing maneuver
|
Colaboradores e Investigadores
Patrocinador
Colaboradores
Investigadores
- Diretor de estudo: Ziv Dadon, MD, Shaare Zedek Medical Center
- Investigador principal: Jason D Roberts, MD MAS, McMaster University
- Investigador principal: Wayne Chen, PhD, University of Calgary
Publicações e links úteis
Publicações Gerais
- Sun B, Yao J, Ni M, Wei J, Zhong X, Guo W, Zhang L, Wang R, Belke D, Chen YX, Lieve KVV, Broendberg AK, Roston TM, Blankoff I, Kammeraad JA, von Alvensleben JC, Lazarte J, Vallmitjana A, Bohne LJ, Rose RA, Benitez R, Hove-Madsen L, Napolitano C, Hegele RA, Fill M, Sanatani S, Wilde AAM, Roberts JD, Priori SG, Jensen HK, Chen SRW. Cardiac ryanodine receptor calcium release deficiency syndrome. Sci Transl Med. 2021 Feb 3;13(579):eaba7287. doi: 10.1126/scitranslmed.aba7287.
- Nof E, Belhassen B, Arad M, Bhuiyan ZA, Antzelevitch C, Rosso R, Fogelman R, Luria D, El-Ani D, Mannens MM, Viskin S, Eldar M, Wilde AA, Glikson M. Postpacing abnormal repolarization in catecholaminergic polymorphic ventricular tachycardia associated with a mutation in the cardiac ryanodine receptor gene. Heart Rhythm. 2011 Oct;8(10):1546-52. doi: 10.1016/j.hrthm.2011.05.016. Epub 2011 May 26.
- Ormerod JOM, Ormondroyd E, Li Y, Taylor J, Wei J, Guo W, Wang R, Sarton CNS, McGuire K, Dreau HMP, Taylor JC, Ginks MR, Rajappan K, Chen SRW, Watkins H. Provocation Testing and Therapeutic Response in a Newly Described Channelopathy: RyR2 Calcium Release Deficiency Syndrome. Circ Genom Precis Med. 2022 Feb;15(1):e003589. doi: 10.1161/CIRCGEN.121.003589. Epub 2021 Dec 24.
- Roston TM, Wei J, Guo W, Li Y, Zhong X, Wang R, Estillore JP, Peltenburg PJ, Noguer FRI, Till J, Eckhardt LL, Orland KM, Hamilton R, LaPage MJ, Krahn AD, Tadros R, Vinocur JM, Kallas D, Franciosi S, Roberts JD, Wilde AAM, Jensen HK, Sanatani S, Chen SRW. Clinical and Functional Characterization of Ryanodine Receptor 2 Variants Implicated in Calcium-Release Deficiency Syndrome. JAMA Cardiol. 2022 Jan 1;7(1):84-92. doi: 10.1001/jamacardio.2021.4458.
- Ni M, Dadon Z, Ormerod JOM, Saenen J, Hoeksema WF, Antiperovitch P, Tadros R, Christiansen MK, Steinberg C, Arnaud M, Tian S, Sun B, Estillore JP, Wang R, Khan HR, Roston TM, Mazzanti A, Giudicessi JR, Siontis KC, Alak A, Acosta JG, Divakara Menon SM, Tan NS, van der Werf C, Nazer B, Vivekanantham H, Pandya T, Cunningham J, Gula LJ, Wong JA, Amit G, Scheinman MM, Krahn AD, Ackerman MJ, Priori SG, Gollob MH, Healey JS, Sacher F, Nof E, Glikson M, Wilde AAM, Watkins H, Jensen HK, Postema PG, Belhassen B, Chen SRW, Roberts JD. A Clinical Diagnostic Test for Calcium Release Deficiency Syndrome. JAMA. 2024 Jul 16;332(3):204-213. doi: 10.1001/jama.2024.8599.
Datas de registro do estudo
Datas Principais do Estudo
Início do estudo (Real)
Conclusão Primária (Estimado)
Conclusão do estudo (Estimado)
Datas de inscrição no estudo
Enviado pela primeira vez
Enviado pela primeira vez que atendeu aos critérios de CQ
Primeira postagem (Real)
Atualizações de registro de estudo
Última Atualização Postada (Real)
Última atualização enviada que atendeu aos critérios de controle de qualidade
Última verificação
Mais Informações
Termos relacionados a este estudo
Palavras-chave
Termos MeSH relevantes adicionais
Outros números de identificação do estudo
- 14546
Plano para dados de participantes individuais (IPD)
Planeja compartilhar dados de participantes individuais (IPD)?
Informações sobre medicamentos e dispositivos, documentos de estudo
Estuda um medicamento regulamentado pela FDA dos EUA
Estuda um produto de dispositivo regulamentado pela FDA dos EUA
Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .